32 results about "Blood platelet counts" patented technology

Provided is a method for assisting in grasping the status of platelet activation, by developing a biomarker that more accurately reflects platelet activation in vivo, said method being usable in testing for thrombotic hemostatic diseases. The method for assisting in grasping the status of platelet activation comprises (1) measuring the concentration of soluble CLEC-2 and a platelet count in a sample obtained from a subject, and (2) calculating a value of [soluble CLEC-2 concentration] / [platelet count] by dividing the soluble CLEC-2 concentration by the platelet count. If desired, the method may further comprise (3) comparing the value with a value of [soluble CLEC-2 concentration] / [platelet count] obtained by using samples from healthy persons.

The present invention provides a pharmaceutical composition for use in a method of treating pulmonary arterial hypertension (PAH). [Solution] A pharmaceutical composition for use in a method for treating pulmonary arterial hypertension (PAH) in a patient in need, comprising an ActRIIA fusion protein, wherein the ActRIIA fusion protein is (i) ActRIIA polypeptide containing a specific amino acid sequence, (ii) Fc domains containing an amino acid sequence that is at least 95% identical to a specific amino acid sequence, (iii) comprising a linker domain located between the ActRIIA polypeptide and the Fc domain, Herein, the ActRIIA fusion protein is administered in a first dose of 0.3 mg / kg and a second dose of 0.7 mg / kg, wherein the second dose is administered after confirming that the patient has an acceptable hemoglobin level and / or platelet count, in a pharmaceutical composition.

The invention relates to a method for constructing a preeclampsia prediction model by using clinical laboratory data and a related application thereof. Specifically, the preeclampsia risk prediction model is constructed based on a plurality of clinical indexes of pregnant women, a plurality of clinical laboratory data and insulin growth binding factor binding protein 1 and / or placental growth factors. The clinical laboratory data comprises leukocyte count and / or urine protein, and further comprises any one or combination of platelet count, monocyte proportion, glutamic-straw / glutamic-pyruvic transaminase ratio, glutamyltranspeptidase, uric acid and high-density lipoprotein. The constructed preeclampsia risk prediction model can provide a reliable implementation means for early prevention and early treatment of preeclampsia. Meanwhile, the sensitivity of the prediction model is 88.0% when the specificity of early eclampsia is 85.04% and the sensitivity of the prediction model is 62.5% when the specificity of late eclampsia is 85.04% in a complete independent verification set, and the detection performance of the prediction model is higher than that of the current detection performance.

The invention relates to a cell image analyzer, a sample analysis system and a cell image analysis method. The cell image analyzer comprises: an imaging device for shooting a cell image; the bearing device is used for bearing the blood smear on which the blood film is applied; the control device is used for controlling the blood smear and the imaging device to move relative to each other, so that a plurality of shooting points in a target area of the blood film are respectively positioned in a visual field of the imaging device, and controlling the imaging device to shoot images of the shooting points in the visual field of the imaging device so as to obtain target cell images of the plurality of shooting points in the target area; the image analysis device is used for identifying platelets in the multiple target cell images and acquiring actual platelet distribution information of the blood membrane based on the platelets identified in the multiple target cell images and the shooting positions of the multiple target cell images in the smearing direction; and based on the actual platelet distribution information, acquiring platelet count and / or judging whether the to-be-detected blood sample is a platelet aggregation sample or not.

The present invention relates to a method of treating idiopathic thrombocytopenic purpura (ITP) in a patient with ITP, comprising: (a) administering romiplostim weekly to the patient; (b) increasing the weekly dose until a platelet count of at least approximately 50 to 200 x 10⁹ / L is achieved; (c) decreasing the weekly dose of romiplostim if the platelet count remains > 200 x 10⁹ / L for two consecutive weeks; (d) permanently discontinuing romiplostim if the platelet count remains > 200 x 10⁹ / L for two consecutive weeks when the weekly dose is 1 µg / kg or the platelet count is > 400 x 10⁹ / L; and (e) if a platelet count > 200 x 109 / L is achieved during the first 4 to 12 weeks of treatment, maintain a treatment-free period of at least approximately 24 weeks during which the patient does not receive romiplostim.

The invention relates to tinostamustine for use in the treatment of lymphoma or a T-cell malignant disease. Tinostamustine may cause side effects when administered to a patient, and it is desirable to minimise such effects. The present invention defines an improved treatment, wherein the dose of tinostamustine administered is varied based on the patient's platelet count.

This disclosure provides processes for preparing cryopreserved platelets, compositions comprising frozen platelets in cryopreservation media, and collections of cryocontainers comprising cryopreserved platelets. In some embodiments, for example at DMSO concentrations, processes for preparing cryopreserved platelets from a platelet pool of two or more donors are provided herein to provide a collection of cryopreserved platelets with improved vial-to-vial and lot-to-lot consistency. Collections of cryocontainers comprising cryopreserved platelets, each having a biomolecular profile representing two or more platelet donors, are also provided herein. Furthermore, compositions comprising frozen platelets are provided herein, which, when stored at a temperature in the range of -10°C to -30°C for at least one month, are capable of yielding a platelet count of at least 1.0 × 10¹¹ / 35 ml of composition, and other enumerated properties.

The embodiments of the present application relate to a platelet counting method and a blood cell analyzer. The method comprises: aspirating a blood sample to be tested; mixing one portion of said blood sample with a diluent to prepare a first test sample, and mixing the other portion of said blood sample with a hemolytic agent and fluorescent dye to prepare a second test sample; performing impedance measurement on the first test sample, in order to obtain an electrical signal of the first test sample; performing optical measurement on the second test sample, in order to obtain at least one optical signal from among a scattered light signal and a fluorescent light signal of the second test sample; at least on the basis of the electrical signal of the first test sample, obtaining platelet distribution information of said blood sample; and at least on the basis of the pulse width of an optical signal among the at least one optical signal that corresponds to platelets in the second test sample, and the platelet distribution information, obtaining a platelet count value. Thus, an accurate platelet count can be obtained at a low cost.

Provided are apparatuses and methods that include imaging a blood sample that is a suspension of cells deposited in a sample chamber. The cells are allowed to settle in the sample chamber to form a monolayer of cells. At least one microscopic image of the monolayer of cells is acquired using a microscope (24) while the microscope is focused at a monolayer depth level, and a first platelet count of platelets that have settled within the monolayer is determined. Additional microscopic images of the sample are acquired while the microscope is focused at depth levels different from the monolayer depth level, and a second platelet count of platelets that are not settled within the monolayer is determined. An output is generated based on the first platelet count and the second platelet count. Other applications are also described.

The invention provides a model for predicting the risk of allergic reaction of a Wilson disease patient during copper expelling treatment, and belongs to the crossing field of clinical medicine and biological information technology. The risk prediction model comprises: an input module receiving patient parameter indexes composed of a sodium dimercaptopropanesulfonate injection dosage, a severe adverse drug reaction, a drug allergy history, a neutrophil count, a lymphocyte count, a ratio of neutrophil to lymphocyte, a ratio of platelets to lymphocyte, a leukocyte count, a urine copper level and a platelet count; the processing module is connected with the input module and is used for calculating the score and prediction probability of the allergic reaction during copper expelling treatment based on the parameter indexes of the patient; and the output module is connected with the processing module, and outputs the allergic reaction risk probability obtained by the risk prediction model during the copper expelling treatment of the Wilson disease patient. The risk prediction model can be conveniently used for early recognition and risk prediction of anaphylaxis of a Wilson disease patient during copper expelling treatment.

This invention discloses a predictive model for early fever and infection after CAR-T therapy. The equation for this predictive model is: P = 1 / (1 + e^(-3.23 + 0.017 × CRP + 0.003 × IL - 6 - 0.023 × platelet count - 8.048 × lymphocyte count - 1.241 × FCV + 1.6146 × neutropenia grade)); where P is the probability of infection. P < 0.20 is defined as low risk, classified as CRS; 0.2 ≤ P ≤ 0.6 is defined as medium risk, requiring further testing to determine whether it is infection or CRS; P > 0.6 is defined as high risk, classified as infection. This predictive model is used to predict the likelihood of infection in the first fever event after CAR-T therapy. By analyzing various clinical laboratory indicators and combining logistic regression analysis, the model screens out key predictive factors related to infection risk, ultimately establishing an efficient and easy-to-use predictive tool. This model can effectively predict the occurrence of infection, provide clinicians with guidance for early intervention, reduce unnecessary clinical testing, and optimize patients' treatment plans.

Citrate has been used as an anticoagulant because of its calcium chelation capability, but it may have unwanted off target metabolic and inflammatory effects; accordingly, alternative anticoagulants may have benefits compared with citrate. Diethylenetriamine pentaacetic acid (DTPA) is an octadentate chelator that is FDA-approved to treat plutonium, americium, and curium exposure by chelation. In this disclosure, it is demonstrated that a composition comprising DTPA, DPDA-1, functions effectively as an anticoagulant for the storage of whole blood, with an increased platelet count and improved viscoelastic properties compared with citrate composition, although DTPA-composition requires half of the amount of calcium to restore clotting function, which suggest DTPA composition's lowering the risk of post transfusion hypocalcemia in comparison to citrate transfusion. Therefore, DTPA-composition is presented here as an anticoagulant to preserve platelets.

A method for constructing a preeclampsia prediction model by using clinical laboratory data and the use thereof. Specifically, the preeclampsia risk prediction model is constructed on the basis of several clinical indexes of pregnant women, several pieces of clinical laboratory data, and insulin-like growth factor-binding protein 1 and / or placental growth factor. The several pieces of clinical laboratory data comprise white blood cell count and / or urine protein, and further comprise any one or a combination of platelet count, monocyte percentage, aspartate aminotransferase / alanine aminotransferase ratio, glutamyl transpeptidase, uric acid and high-density lipoprotein. The constructed preeclampsia risk prediction model can provide a reliable implementation means for early prevention and early treatment of preeclampsia. Moreover, in a fully independent validation set, when the specificity of the prediction model for early-onset preeclampsia is 85.04%, the sensitivity is 88.0%, and when the specificity for late-onset preeclampsia is 85.04%, the sensitivity is 62.5%, outperforming the current detection performance.

The embodiment of the invention relates to a platelet counting method and a blood cell analyzer. The method comprises the following steps: adding a diluent and a fluorescent dye into a to-be-tested blood sample to obtain the to-be-tested blood sample; light measurement is conducted on the to-be-measured sample to obtain forward scattering light signals of all particles in the to-be-measured sample, and each forward scattering light signal comprises forward scattering light pulse intensity and forward scattering light pulse width; and obtaining a platelet count value of the to-be-tested blood sample at least based on the forward scattering light pulse intensity and the forward scattering light pulse width in the forward scattering light signal of each particle in the to-be-tested sample. Therefore, accurate platelet counting can be obtained through one-time platelet optical detection.

The invention discloses a method, a device, equipment and a medium for predicting the reaching of pCR of neoadjuvant chemotherapy of triple negative breast cancer, and relates to the technical field of medical data processing, and the method comprises the following steps: obtaining clinical pathological characteristics of a to-be-detected object and peripheral blood counting data before neoadjuvant chemotherapy; the peripheral blood count data comprises neutrophil count, lymphocyte count, platelet count and mononuclear cell count; the clinical pathological characteristics comprise a T staging characteristic, an N staging characteristic and a Ki-67 characteristic; determining a target biomarker related to pathologic complete remission pCR prediction based on the peripheral blood count data, and calculating an immune inflammation score according to the target biomarker; the clinical pathological features and the immune inflammation scores are processed through a trained XGB model, and a pCR prediction result of the to-be-detected object is obtained; and the XGB model is used for capturing a nonlinear relationship and an interaction effect among the data. According to the invention, the problem of poor detection timeliness can be avoided, and the pCR prediction accuracy is improved at the same time.

This invention provides a platelet counting method that enables highly sensitive and stable platelet counting even after a significant amount of time has passed since blood collection. [Solution] A platelet counting method comprising bringing a collected blood sample 20 into contact with a substrate 12 having a platelet-solid phase portion 14 on its surface, and washing the substrate 12 to which the blood sample 20 has adhered while the platelets 26 contained in the blood sample 20 are solidified on the substrate 12.

The invention discloses a platelet, blood sugar and blood coagulation function joint detection chip, a detection device and a detection method, and belongs to the field of biomedical engineering. The invention discloses a platelet, blood sugar and blood coagulation function joint detection chip, a detection device and a detection method. The platelet, blood sugar and blood coagulation function joint detection chip comprises a micro-fluidic chip, a driving and control system, a detection and sensing system and a data processing and output system. The problems that in the prior art, key indexes such as platelet counting, blood sugar and blood coagulation functions need to depend on different devices, the process is tedious, consumed time is long, and the rapid diagnosis requirement of emergency treatment cannot be met due to step-by-step detection are solved, automatic separation and accurate distribution of whole blood samples are achieved through the integrated layered flow channel design, and the detection efficiency is improved. A multi-band optical detection and quantum dot fluorescence imaging technology is combined, and a multi-mode and high-sensitivity real-time signal acquisition system is established, so that multi-index automatic, parallel and rapid detection after whole blood sample injection is realized on a single chip platform, and the detection efficiency and the result reliability are greatly improved.

Methods and materials that can be used to measure the concentration of platelets in whole blood samples (e.g., at the point of care) are provided herein.

The invention discloses an in-vitro sample detection data-based decompensated liver cirrhosis risk assessment method and a related device, and relates to the technical field of liver cirrhosis condition assessment. The method comprises the following steps: acquiring in-vitro detection sample data corresponding to a to-be-assessed blood sample, the in-vitro detection sample data comprises sCD146, prothrombin time, serum albumin and platelet count; performing data preprocessing on the in-vitro detection sample data, namely generating a serum albumin grade variable ALBgrade based on a preset grading threshold value according to the numerical value of the serum albumin; inputting the processed feature data into a pre-trained binary Logistic regression model, and outputting a decompensated liver cirrhosis risk value corresponding to the to-be-evaluated blood sample; the decompensated liver cirrhosis risk value is a prediction probability P output by the binary Logistic regression model. The method can effectively improve the evaluation accuracy of decompensated liver cirrhosis.

The application discloses an AI fusion enabled CRRT intelligent anticoagulation decision system, and relates to the technical field of intelligent control of medical equipment.The system comprises a data acquisition module, a data preprocessing module, an AI calculation module, a decision output module and a control interface module.The application constructs a hybrid AI model with fusion space and time sequence feature extraction capability, realizes multidimensional and dynamic precise modeling of the complex problem of CRRT anticoagulation decision, uses a convolutional neural network (CNN) to mine deep spatial correlation features among patient weight, coagulation indicators and platelet count static parameters, simultaneously uses a long short-term memory network (LSTM) to process high-frequency time sequences formed by transmembrane pressure and filter pressure machine parameters, and learns dynamic rules of filter performance attenuation and subtle trends of coagulation precursors from the time sequences, so that the system can generate an optimal parameter trajectory that is self-adaptively adjusted with the evolution of the system state based on the current instantaneous system state.

Apparatus and methods are provided including imaging a blood sample that is a cell suspension deposited in a sample chamber. The cells are allowed to settle in the sample chamber to form a monolayer of cells. At least one microscopic image is acquired of the monolayer of cells using a microscope (24) while the microscope is focused at a monolayer-depth-level, and a first platelet count of platelets that have settled within the monolayer, is determined. An additional microscopic image of the simple is acquired, while the microscope is focused at a different depth level from the monolayer-depth-level, and a second platelet count of platelets that have not settled within the monolayer is determined. An output is generated based upon the first and second platelet counts. Other applications are also described.

The embodiment of the invention provides a children sirolimus administration dosage prediction method, equipment, a medium and a program product, and relates to the field of intelligent medical treatment. The method comprises the following steps: acquiring prediction parameter information of a to-be-detected sample, wherein prediction parameters comprise weight, age, platelet count and creatinine; inputting the prediction parameter information into the dose prediction model, and calculating the predicted dose of sirolimus; the predicted dose is the daily average dose in the stable treatment period. The application develops an administration dosage prediction model aiming at three clinical problems of dosage error caused by development dynamics, high-risk group medication risk and passive decision mode in children sirolimus administration.

The present invention relates to a method for diagnosing the risk of non-alcoholic steatohepatitis (NAS) in a human patient with a metabolic disorder, comprising: (i) calculating a non-alcoholic fatty liver disease (NFD) score from the patient's age, body mass index (BMI), aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ratio, platelet count, and hyperglycemic status; and (ii) calculating a non-alcoholic steatohepatitis score (NIS4) for the patient based on the levels of hsa-miR-34a-5p, alpha-2-macroglobulin (A2M), YKL-40, and glycosylated hemoglobin (HbA1c), measured in a blood sample or blood derivative from the patient; and determining the presence or absence of NAS risk in the patient based on these scores. where the NFS test is implemented before or after the NIS4 test.

The present disclosure provides collections of cryo-vessels and compositions comprising cryopreserved platelets, for example frozen activated platelets, comprising a population of platelet particles in a cryopreservation medium in a frozen state. Such collections and compositions can include cryopreserved platelets having a biomolecule profile indicative of more than 1 platelet donor and can have various additional disclosed properties. Also provided herein, in some aspects are processes for preparing a batch of cryopreserved platelet compositions, and methods for reducing bleeding in a subject comprising administering cryopreserved platelets provided herein. In some aspects, provided herein are processes for preparing cryopreserved platelets from a platelet pool of more than 1 donor to provide collections of cryopreserved platelets with improved vial to vial and lot to lot consistency for example, in DMSO concentration. Also provided herein is a collection, a composition, and a process of preparing a batch of cryopreserved platelets in cryo-vessels that upon thawing and storing at room temperature for at least 8 hours have the property of exhibiting a pH of greater than 6.2. Furthermore, provided herein are compositions comprising frozen platelets that when stored at a temperature in a range of −10° C. to −30° C., for at least 1 month are capable of yielding a platelet count of at least 1.0×1011 / 35 ml of the composition and other disclosed properties.

The present disclosure relates to a use of Herombopag or a pharmaceutically acceptable salt thereof in treatment of tumor chemotherapy-induced thrombocytopenia. Specifically, the present disclosure relates to a disease treatment method, comprising: administering to a patient Herombopag or a pharmaceutically acceptable salt thereof, which can significantly increase the blood platelet count of a subject.

Provided herein are methods and materials useful for measuring platelet concentration in a whole blood sample (e.g., at the point of care).

The invention discloses a dynamic monitoring method and system for a skin bleeding point image in a myelosuppression period of a chemotherapy patient, and belongs to the technical field of medical image processing, and the method comprises the steps: collecting a skin image through a standardized device provided with an annular light source and a color card reference; performing color correction and skin color normalization processing; color threshold segmentation and morphological analysis are adopted to identify blood stasis spot, ecchymosis and purpura areas and distinguish new and old blood stasis spots; calculating quantitative indexes such as hemorrhagic point quantity, area and density, and comparing with historical image registration to analyze a change trend; and dynamically adjusting the monitoring frequency according to the platelet count and the hemorrhagic point change trend and triggering hemorrhagic risk early warning.

Reanalysis of the SIMPLIFY 1 and 2 trials data indicates MMB is effective in JAKi-naïve patients and in second line therapy to RUX, providing benefits of reducing enlarged spleens, improving myelofibrosis-related symptoms, and increasing transfusion independence in patient at risk for thrombocytopenia from the underlying disease and RUX therapy. Accordingly, methods of treating myeloproliferative neoplasms (MPN) such as myelofibrosis are described. The methods can include administering a therapeutically effective amount of momelotinib or a pharmaceutically acceptable salt thereof to a subject identified as having (i) myelofibrosis and (ii) a platelet count of less than 150×109 / L. Also described are methods including administering to a subject with myelofibrosis a therapeutically effective stable dose of momelotinib or a pharmaceutically acceptable salt thereof, for a period of a plurality of weeks, where the subject is assessed as maintaining a platelet count above a predetermined threshold platelet count during the period.

Methods and materials that can be used to measure the concentration of platelets in whole blood samples (e.g., at the point of care) are provided herein.

The invention discloses a clotting reserve index (CRI) calculation method and system for blood purification opportunity decision. The method comprises the following steps: measuring platelet count, fibrinogen and D-dimer in real time, and calculating an index according to CRI = (FIB * PLT) / D-dimer; when CRIlt; and 5, judging that the blood clotting storage is insufficient, outputting a blood purification taboo signal and suggesting to give cryoprecipitation. According to the present invention, two ACDMB poisoning cases are verified at 26 time points, 5, the AUC of DIC deterioration within 24 hours is predicted to be 0.92, so that the DIC risk related to blood purification is reduced by 72.5%, and the rehabilitation time is shortened by 39.4%. The system can be embedded into existing blood purification equipment, is simple, convenient and real-time, does not need additional reagents, and is suitable for common wards with limited resources.